OVER THE PAST DECADE, there has been a significant decline in cardiac surgery–
associated mortality, despite an increase in procedural complexity. Although the average …

Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Background: This study evaluated the efficacy and safety of levosimendan, a positive
inotropic drug with vasodilator effects, given intravenously to patients with acutely …

Background Levosimendan, a novel calcium sensitiser, improves myocardial contractility
without causing an increase in myocardial oxygen demand. We compared the effects of …

ContextBecause acute decompensated heart failure causes substantial morbidity and
mortality, there is a need for agents that at least improve hemodynamics and relieve …

of the guidelines on the diagnosis and treatment of acute heart failure | European Heart Journal
| Oxford Academic Skip to Main Content Advertisement intended for healthcare professionals …

Aims To evaluate the safety and efficacy of levosimendan in patients with left ventricular
failure complicating acute myocardial infarction. Methods and Results Levosimendan at …

Background Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) as
complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery are …

Introduction Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting
right ventricular (RV) failure occur in many critical illnesses and may be associated with a …

Background Inotropes and vasopressors are frequently administered to critically ill patients
in order to improve haemodynamic function and restore adequate organ perfusion …